Company intelligence / Profile preview

MASU

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Masu is an early-stage biotechnology company focused on developing a novel class of induced proximity medicines. The company's platform leverages small molecules to recruit specific cellular machinery, such as E3 ligases, to modulate the stability or function of disease-causing proteins. By focusing on targets that have traditionally been considered undruggable, Masu aims to create transformative therapies for oncology and inflammatory conditions. The company is currently in the pre-clinical stage, optimizing its lead candidates and expanding its discovery pipeline.

Therapeutic areas: ImmunologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MASU.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MASU.

Explore the full profile